Inventor · disambiguated record
Rimas J. Orentas
Also filed as: ORENTAS RIMAS · ORENTAS RIMAS J
42 granted patents·19 pending applications·249 citations·filing 2012–2025
98Inventor score
Files withLENTIGEN TECH INC41US HEALTH9LENTIGENTECHNOLOGY INC3SEATTLE CHILDRENS HOSPITAL DBA SEATTLE CHILDRENS RES INST2THE UNITED STATES OF AMERICA AS PRESENTED BY THE SEC DEP OF HEALTH AND HUMAN SERVICES2
Top patents by PatentIndex Score
61 records- 0197US10844128B2Compositions and methods for treating cancer with anti-CD123 immunotherapyLENTIGEN TECH INC·Filed 2019·Granted Nov 24, 2020·20 cites·11 claims
- 0297US10442867B2Compositions and methods for treating cancer with anti-CD19/CD20 immunotherapyLENTIGEN TECH INC·Filed 2018·Granted Oct 15, 2019·17 cites·7 claims
- 0397US10428141B2Compositions and methods for treating cancer with anti-ROR1 immunotherapyLENTIGEN TECH INC·Filed 2018·Granted Oct 1, 2019·15 cites·13 claims
- 0496US11242389B2Compositions and methods for treating cancer with anti-CD19/CD22 immunotherapyLENTIGEN TECH INC·Filed 2020·Granted Feb 8, 2022·5 cites·20 claims
- 0596US10183993B2Compositions and methods for treating cancer with anti-mesothelin immunotherapyLENTIGEN TECH INC·Filed 2018·Granted Jan 22, 2019·11 cites·27 claims
- 0696US9868774B2Anti-CD22 chimeric antigen receptorsUS HEALTH·Filed 2012·Granted Jan 16, 2018·36 cites·20 claims
- 0796US9790282B2Anti-CD276 polypeptides, proteins, and chimeric antigen receptorsUS HEALTH·Filed 2014·Granted Oct 17, 2017·28 cites·29 claims
- 0895US11208455B2Compositions and methods for treating cancer with DuoCARsLENTIGEN TECH INC·Filed 2019·Granted Dec 28, 2021·6 cites·8 claims
- 0995US10689431B2Compositions and methods for treating cancer with DuoCARsLENTIGEN TECH INC·Filed 2018·Granted Jun 23, 2020·8 cites·9 claims
- 1095US10543263B2Compositions and methods for treating cancer with anti-CD22 immunotherapyLENTIGENTECHNOLOGY INC·Filed 2018·Granted Jan 28, 2020·14 cites·12 claims
- 1195US10501539B2Compositions and methods for treating cancer with anti-CD19 immunotherapyLENTIGEN TECH INC·Filed 2018·Granted Dec 10, 2019·8 cites·6 claims
- 1295US10426797B2Compositions and methods for treating cancer with anti-CD33 immunotherapyLENTIGEN TECH INC·Filed 2018·Granted Oct 1, 2019·19 cites·10 claims
- 1393US11103533B2Compositions and methods for treating cancer with anti-CD38 immunotherapyLENTIGEN TECH INC·Filed 2019·Granted Aug 31, 2021·7 cites·13 claims
- 1493US10639329B2Method to treat cancer with engineered T-cellsLENTIGEN TECH INC·Filed 2016·Granted May 5, 2020·12 cites·6 claims
- 1593US10550179B2Compositions and methods for treating cancer with anti-mesothelin immunotherapyLENTIGEN TECH INC·Filed 2019·Granted Feb 4, 2020·6 cites·18 claims
- 1692US10822412B2Compositions and methods for treating cancer with anti-CD19/CD22 immunotherapyLENTIGENTECHNOLOGY INC·Filed 2019·Granted Nov 3, 2020·6 cites·14 claims
- 1792US10703816B2M971 chimeric antigen receptorsUS HEALTH·Filed 2018·Granted Jul 7, 2020·3 cites·18 claims
- 1889US11453712B2Compositions and methods for treating cancer with DuoCARsLENTIGEN TECH INC·Filed 2017·Granted Sep 27, 2022·2 cites·8 claims
- 1988US10072078B2M971 chimeric antigen receptorsUS HEALTH·Filed 2013·Granted Sep 11, 2018·7 cites·18 claims
- 2087US11453719B2Compositions and methods for treating cancer with anti-ROR1 immunotherapyLENTIGEN TECH INC·Filed 2019·Granted Sep 27, 2022·2 cites·19 claims
- 2187US2024043497A1Compositions and Methods for Treating Cancer with DuoCARsLENTIGEN TECH INC·Filed 2023·Application pending·0 cites
- 2287US2025367291A1Compositions and Methods for Treating Cancer with DuoCARsLENTIGEN TECH INC·Filed 2025·Application pending·0 cites
- 2386US11802142B2Compositions and methods for treating cancer with DuoCARsLENTIGEN TECH INC·Filed 2020·Granted Oct 31, 2023·1 cites·7 claims
- 2486US2024025962A1Compositions and methods for treating cancer with duocarsLENTIGEN TECH INC·Filed 2023·Application pending·0 cites
- 2585US10421810B2Chimeric antigen receptors and methods of useMILTENYI BIOTEC TECH INC·Filed 2016·Granted Sep 24, 2019·6 cites·19 claims
- 2685US2024084008A1M971 chimeric antigen receptorsUS HEALTH·Filed 2023·Application pending·0 cites
- 2785US2024084007A1M971 chimeric antigen receptorsUS HEALTH·Filed 2023·Application pending·0 cites
- 2884US10894819B2Compositions and methods for treating HIV/AIDS with immunotherapyLENTIGEN TECH INC·Filed 2018·Granted Jan 19, 2021·2 cites·18 claims
- 2984US10738116B2Dual specific anti-CD22-anti-CD19 chimeric antigen receptorsTHE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY DEPT OF HEALTH AND HUMAN SERVICES·Filed 2016·Granted Aug 11, 2020·3 cites·24 claims
- 3082US11878052B2Compositions and methods for treating cancer with anti-CD22 immunotherapyLENTIGENTECHNOLOGY INC·Filed 2020·Granted Jan 23, 2024·1 cites·19 claims
- 3182US11078286B2Monoclonal antibodies specific for fibroblast growth factor receptor 4 (FGFR4) and methods of their useUS HEALTH·Filed 2016·Granted Aug 3, 2021·2 cites·9 claims
- 3282US2022281946A1Compositions and Methods for Treating Cancer with DuoCARsLENTIGEN TECH INC·Filed 2022·Application pending·0 cites
- 3381US12365718B2Compositions and methods for treating cancer with DuoCARsLENTIGEN TECH INC·Filed 2021·Granted Jul 22, 2025·0 cites·8 claims
- 3481US11464801B2Compositions and methods for treating cancer with anti-CD33 immunotherapyLENTIGEN TECH INC·Filed 2019·Granted Oct 11, 2022·1 cites·15 claims
- 3580US2025084166A1Compositions and Methods for Treating Cancer with Anti-CD19/CD22 ImmunotherapyLENTIGEN TECH INC·Filed 2024·Application pending·0 cites
- 3680US2024067724A1Compositions and Methods for Treating Cancer with Anti-CD19 ImmunotherapyLENTIGEN TECH INC·Filed 2023·Application pending·0 cites
- 3779US2024108706A1Compositions and Methods for Treating Cancer with Anti-CD22 ImmunotherapyLENTIGEN TECH INC·Filed 2023·Application pending·0 cites
- 3879US2024150773A1Chimeric Antigen Receptors and Methods of UseLENTIGEN TECH INC·Filed 2024·Application pending·0 cites
- 3979US2025090631A1Method to Treat Cancer with Engineered T-CellsLENTIGEN TECH INC·Filed 2024·Application pending·0 cites
- 4079US2023110875A1Anti-cd276 polypeptides, proteins, and chimeric antigen receptorsTHE UNITED STATES OF AMERICA AS PRESENTED BY THE SEC DEP OF HEALTH·Filed 2022·Application pending·0 cites
- 4178US2024309102A1Compositions and Methods for Treating Cancer with Anti-CD123 ImmunotherapyLENTIGEN TECH INC·Filed 2024·Application pending·0 cites
- 4278US2024368256A1Compositions and methods for treating hiv/aids with immunotherapyLENTIGEN TECH INC·Filed 2024·Application pending·0 cites
- 4377US10604583B2Anti-CD276 polypeptides, proteins, and chimeric antigen receptorsTHE UNITED STATES OF AMERICA AS PRESENTED BY THE SEC DEP OF HEALTH AND HUMAN SERVICES·Filed 2017·Granted Mar 31, 2020·1 cites·22 claims
- 4477US2024034802A1Compositions and methods for treating cancer with anti-cd19/cd20 immunotherapyLENTIGEN TECH INC·Filed 2023·Application pending·0 cites
- 4576US12371490B2Compositions and methods for treating cancer with anti-CD19/CD22 immunotherapyLENTIGEN TECH INC·Filed 2022·Granted Jul 29, 2025·0 cites·27 claims
- 4676US11905515B2Chimeric antigen receptors and methods of useLENTIGEN TECH INC·Filed 2019·Granted Feb 20, 2024·0 cites·2 claims
- 4775US11708408B2Compositions and methods for treating cancer with anti-CD19 immunotherapyLENTIGEN TECH INC·Filed 2019·Granted Jul 25, 2023·0 cites·17 claims
- 4874US2023241103A1Compositions and Methods for Treating Cancer with Anti-CD33 ImmunotherapyLENTIGEN TECH INC·Filed 2022·Application pending·0 cites
- 4973US11807682B2M971 chimeric antigen receptorsUS HEALTH·Filed 2020·Granted Nov 7, 2023·0 cites·26 claims
- 5072US12453780B2Monoclonal antibodies specific for fibroblast growth factor receptor 4 (FGFR4) and methods of their useUS HEALTH·Filed 2021·Granted Oct 28, 2025·0 cites·20 claims
Showing the top 50 of 61 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Rimas J. Orentas files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →